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Specialized metabolic sensors in the hypothalamus regulate blood glucose levels by influencing
hepatic glucose output and hypoglycemic counterregulatory responses. Hypothalamic reactive
oxygen species (ROS) may act as a metabolic signal-mediating responses to changes in glucose,
other substrates and hormones. The role of ROS in the brain’s control of glucose homeostasis
remains unclear.We hypothesized that hydrogen peroxide (H2O2), a relatively stable form of ROS,
acts as a sensor of neuronal glucose consumption and availability and that lowering brain H2O2
with the enzyme catalase would lead to systemic responses increasing blood glucose. During
hyperinsulinemic euglycemic clamps in rats, intracerebroventricular catalase infusion resulted in
increased hepatic glucose output, which was associated with reduced neuronal activity in the
arcuate nucleus of the hypothalamus. Electrophysiological recordings revealed a subset of arcuate
nucleus neurons expressing proopiomelanocortin that were inhibited by catalase and excited by
H2O2.Duringhypoglycemic clamps, intracerebroventricular catalase increasedglucagonandepineph-
rine responses to hypoglycemia, consistentwith perceived lower glucose levels. Our data suggest that
H2O2 represents an important metabolic cue, which, through tuning the electrical activity of key
neuronal populations such as proopiomelanocortin neurons, may have a role in the brain’s influence
of glucose homeostasis and energy balance. (Endocrinology 157: 4669–4676, 2016)
Glucose is a key cellular fuel essential for life whoseblood concentration in healthy individuals is ac-
tively maintained within a narrow range. Hyperglyce-
mia leads to a compensatory increase in peripheral
glucose uptake and/or a decrease in hepatic glucose pro-
duction (1). Hypoglycemia results in a reversal of these
effects and, if blood glucose falls low enough, the trig-
gering of an array of counterregulatory neurohumoral
responses (2). The hypothalamus has a key role in reg-
ulating these homeostatic, blood glucose-controlling,
mechanisms, acting via both humoral outflows (eg, in-
creased ACTH release stimulating glucocorticoid re-
sponses to hypoglycemia) but also via autonomic neural
outflow to liver, pancreas, and adrenal medulla (3). Ac-
cordingly, subsets of neurons within the hypothalamus
including proopiomelanocortin (POMC) and others
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such as agouti-related peptide-expressing populations
have been shown to respond to changes in extracellular
glucose concentration (4–6) through a process likely to
involve uptake and metabolism of glucose molecules
(7–9). Circulating hormones such as insulin may also
act in the hypothalamus to alter hepatic glucose fluxes
(10), possibly acting on glucose-sensing neurons that
therefore act as broader metabolic sensors.
Recent data suggest that hypothalamic reactive oxygen
species (ROS) may act as a metabolic signal in response to
changes in substrates and hormonal signals leading to
changes in peripheral metabolism and energy balance. A
rise in glucose or lipid metabolismmay result in a burst of
hypothalamic ROS mediating a rise in pancreatic insulin
secretion and/or decreased appetite (11). Insulin may also
stimulate hypothalamic ROS (12) and ROS have been im-
plicated in peripheral insulin signaling (13). Furthermore,
exogenous delivery of ROS to the hypothalamus has been
shown to stimulate POMC neurons (14), cells typically
activatedbynutrient signals, includingglucose (15).These
studies have largely examined the sensing of oxidative
stress in general, a process that involves a number of dif-
ferent molecular signals. Of the numerous types of ROS,
hydrogen peroxide (H2O2) has been proposed as themost
suitable candidate for a role as a messenger molecule due
to its enzymatic production, degradation and limited ox-
idation targets (16)
In thiswork,we assessed the influence of hypothalamic
H2O2 signaling on peripheral insulin sensitivity during
euglycemia, on the triggering of hypoglycemic counter-
regulatory responses and the cellular activity of arcuate
nucleus of the hypothalamus (ARC) POMC neurons.
Materials and Methods
All procedures were approved in advance by both local
and national ethical review processes and conducted in
accordance with the United Kingdom Home Office wel-
fare guidelines under the animal scientific procedures act
(1986). Male Sprague Dawley rats (Charles River Labo-
ratories) weighing 250–350 g were used for in vivo stud-
ies. For ex vivo electrophysiological studies, transgenic
mice expressing a red fluorescent protein driven by Pomc
neuronal regulatory elements (POMCDsRed) aged between
2 and 6months were used (17). Standard chow and water
were available ad libitum except when specified. Chemi-
cals were from Sigma-Aldrich unless stated.
Surgery
Vascular catheters were placed in carotid artery and jugular
vein and a guide cannula was inserted stereotaxically aimed at
the base of the third ventricle, 0.9mm lateral and 2.2mm caudal
to the bregma, 8.4 mm ventral from the dura, at a 5° angle
towards midline, as previously described (18). Surgery was per-
formed under inhaled anesthesia with routine perioperative an-
tibiotic and analgesia. Experiments were performed after full
recovery, 7–10 days after surgery.
Euglycemic clamps with ICV catalase
After an overnight food restriction of 16 g, catheterized rats
underwent a 180-minute euglycemic “pancreatic” clamp (Figure
1, A and B). In short, a (nonprimed) continuous 2-mU/kg  min
insulin intravascular infusion was delivered together with
3-g/kg  min somatostatin and 20% dextrose, with the rate of
the latter adjusted according to serial plasma glucose measure-
ments. Additionally, rats received a 0.9-g/kg  min infusion of
carbon 13-labeled glucose tracer ([U-13C6]D-glucose; GK Gas
Products Ltd) starting 180 minutes before the start of the insulin
infusion (primed for first 8 minutes at 4.5 g/kg  min) and con-
tinuing throughout theclamp.Ratsalso receivedan ICVinfusionof
either 4.5-mU/min catalase or control artificial extracellular fluid
(ECF) starting 90 minutes before and continuing throughout the
clamp. Typically, 2 animals were studied in parallel (1 control and
1 ICV catalase). During clamp studies, plasma samples were col-
lected for analysis of insulin levels at 150 and 180 minutes and for
13C6 D-glucose at 150, 160, 170, and 180 minutes.
Figure 1. In vivo studies design. A, Rats underwent surgery for
insertion of vascular catheters to carotid artery and jugular vein and a
third ventricle ICV cannula. Insulin clamp studies were conducted 5–10
days later. For the night preceding the study day, the rats were
restricted to 16 g of chow (euglycemic clamps) or fasted (hypoglycemic
clamps). On the study day, rats were randomized to receive either ICV
infusion of catalase or ECF and euglycemic (B) or hypoglycemic (C)
clamps were performed as shown.
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Hyperinsulinemic hypoglycemic clamps with ICV
catalase
After an overnight fast, catheterized rats underwent a 120-
minute stepwise hypoglycemic clamp with a primed continuous
20-mU/kg  min insulin infusion together with a simultaneous
infusion of 20% dextrose, with the rate of the latter adjusted
according to serial plasma glucose measurements (Figure 1, A
and C). The target plasma glucose was 5mM for the first 40
minutes of the clamp, 3.5mM for the second stage, and 2.5mM
in the final 40minutes. Blood sampling for assessment of insulin,
epinephrine, and glucagon was done at the end of each stage. As
above, the rats received either ICV infusion of 4.5-mU/min cat-
alase or ECF starting 90minutes before and continuing through-
out the clamp, againwith ICV catalase and control animals stud-
ied in parallel.
Glucose and hormone assays
Blood glucose was measured on 5- to 10-L plasma samples
using a bench top glucose analyzer utilizing the glucose oxidase
method (Analox GM9; Analox Instruments). Plasma [U-13C6]D-
glucose concentration enrichments were determined using gas
chromatography-mass spectrometry (19). Plasma hormone con-
centrations (glucagon and epinephrine) were determined using
ELISA (Linco).
Tissue collection
Forty-five to 60 minutes after completion of euglycemic
clamps, the rats were euthanized with a 1-mL ip injection of
sodium pentobarbital. Samples of liver were collected on dry ice
for analysis of gluconeogenic enzyme expression. The brains
were perfused with 10% formaldehyde, saturated with 20% su-
crose and stored in PBS azide until histological confirmation of
ICV cannula placement and c-Fos immunohistochemical stain-
ing as previously described (20). Mean c-Fos activation in the
ARC was quantified in bregma levels 1.9 to 3.8 mm and
expressed as average counts/view.
Ex vivo electrophysiology
For electrophysiological experiments, POMCDS-RED mice
were anesthetized with sodium pentobarbital (Euthatal) and de-
capitated. The brain was rapidly removed and placed in cold,
oxygenated (95%O2/5%CO2) “slicing” solution containing
214mM sucrose, 2.0mM KCl, 1.2mM NaH2PO4, 26mM
NaHCO3, 4mMMgSO4, 0.1mMCaCl2, and 10mMD-glucose.
The brain was glued to a vibratingmicrotome (Campden Instru-
ments), and 200-m-thick coronal sections of the hypothalamus
containing the ARC were prepared. Slices were immediately
transferred to a “recording” solution containing 127mMNaCl,
2.0mM KCl, 1.2mM NaH2PO4, 26mM NaHCO3, 1.3mM
MgCl2, 2.4mM CaCl2, and 5mM D-glucose, in a continuously
oxygenated holding chamber at 35°C for a period of 25minutes.
Subsequently, slices were allowed to recover in recording solu-
tion at room temperature for a minimum of 1 hour before re-
cording. For whole-cell recordings, slices were transferred to a
submerged chamber and a Slicescope upright microscope (Sci-
entifica) was used for infrared-differential interference contrast
and fluorescence visualization of cells. During recording, unless
otherwise described, slices were continuously perfused at a rate
of approximately 2 mL/min with oxygenated recording solution
(as above) maintained at 32°C with an inline heater. All phar-
macological compounds were bath applied. No synaptic block-
erswere added.Neuronswhosemembrane potential changed by
greater than 4 mV within 10 minutes of compound application
were considered responsive.
Whole-cell current-clamp recordings were performed with
pipettes (3–7 M when filled with intracellular solution) made
fromborosilicate glass capillaries (World Precision Instruments)
pulled on a P-97 Flaming/Brown micropipette puller (Sutter).
The intracellular recording solution contained 140mM K-glu-
conate, 10mM KCl, 10mM HEPES, 1mM EGTA, and 2mM
Na2ATP (pH7.3;withKOH).Recordingswere performedusing
a Multiclamp 700B amplifier and pClamp10 software (Molec-
ular Devices). Access resistance was monitored throughout the
experiments, andneurons inwhich the series resistancewasmore
than 25M or changedmore than 15%were excluded from the
statistics. Liquid junction potential was 16.4 mV and not com-
pensated. The recorded signal was sampled at 10 kHz and fil-
tered at 2 kHz unless otherwise stated.
Data were examined using either parametric (Student’s t test
or two-way ANOVA) or nonparametric (unpairedMann-Whit-
ney) tests in SPSS 23.0withP .05 as significance level.Data are
presented as mean  SEM.
Results
ICV infusion of catalase increases hepatic glucose
output during euglycemic clamp
Catalase is an enzyme that breaks down H2O2, one of
the most stable forms of biological ROS (16). We exam-
ined the effect of third ventricle ICV catalase infusion on
glucose homeostasis during euglycemic clamps in rats. In
keeping with our hypothesis of brain H2O2 acting as a
sensor of glucose metabolism, ICV catalase significantly
reduced the dextrose infusion required to maintain a
similar level of euglycemia during the steady state of the
euglycemic clamp in comparison with vehicle controls
(Figure 2, A and B).
Analysis of glucose fluxes using [U-13C6]D-glucose re-
vealed an increase in hepatic glucose output of catalase-
infused rats (Figure 2C) but no difference in glucose dis-
appearance between the 2 groups (Figure 2D).
ICV infusion of catalase reduces c-Fos activation in
the ARC
Neuronal activity in theARCtriggeredby intravascular
glucose has been proposed to be conditional on the pro-
duction of ROS (21). After observation that ICV catalase
infusion leads to systemic responses consistent with the
reduced perception of glucose, we assessed the effects of
ICV catalase on neuronal activation in the ARC during
euglycemic clamps. We observed that third ventricle in-
fusion of catalase significantly reduced c-Fos immunore-
activity in the ARC (Figure 2G). Although we did not
examine the immunohistochemical identity of the popu-
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lation(s) of neurons affected, anorexigenic POMC neu-
rons are a likely candidate as they have been shown to be
activated by an increase in both glucose and its metabolic
biproduct H2O2 (14, 15).
Arcuate POMC neurons are
inhibited by catalase and
activated by H2O2
To determine the effect of H2O2
and H2O2 scavenging upon arcuate
POMC neuronal activity ex vivo, we
prepared acute hypothalamic brain
slices from POMCDS-Red animals and
obtained whole-cell recordings from
fluorescently identified POMC neu-
rons. Application of 1.5mMH2O2 re-
sulted in 100%(8/8) of neurons tested
undergoingmembranedepolarization
andan increase in actionpotential dis-
charge (Figure 3, A and D). Applica-
tion of catalase (500 U/mL) induced
the opposite effect, causing 89% (8/9)
of neurons tested to undergo mem-
brane hyperpolarization and an asso-
ciated inhibition of action potential
discharge (Figure 3, B and D). Fur-
thermore, administration of the cata-
lase inhibitor 3-amino-1,2,4-triazole
(ATZ), which would presumably re-
sult in reduction in ROS scavenging
and an associated increase in endoge-
nousH2O2,mimicked the effect of di-
rect H2O2 application causing a de-
crease in membrane potential and
increase in action potential discharge
in 75% (3/4) of neurons tested (Figure
3, C and D). These results demon-
strate the ability of catalase availabil-
ity to bidirectionally modulate the
activity of a key population of glucose
sensing neurons implicated in the regu-
lation peripheral glucose homeostasis.
ICV infusion of catalase
increases counterregulatory
responses to hypoglycemia
To examine the contribution of
H2O2 signaling to the control of
counterregulatory responses to hy-
poglycemia, we performed hyperin-
sulinemic hypoglycemic clamps in
rats receiving ICV catalase. In keep-
ing with our hypothesis that reduced
H2O2 levels in the brain would be
interpreted as reduced blood glucose levels, ICV infusion
of catalase significantly increased the adrenaline produced
as part of the counterregulatory response to hypoglycemia
Figure 2. ICV infusion of catalase increases hepatic glucose output. A, Plasma glucose levels
were matched between catalase and ECF groups. Inset, Plasma U-13C D-glucose levels were
steady during last 45 minutes of clamps and lower in ECF group (P  .01; two-way ANOVA for
group effect). B, Dextrose infusion rates during last 45 minutes of clamps were lower in catalase
group (P  .001; two-way ANOVA for both time and group effects). C, ICV catalase significantly
increased the steady state endogenous glucose production. D, The glucose disposal rate did not
differ significantly between the 2 groups. E, Plasma insulin concentrations were similar in ECF
and catalase groups throughout. F, ICV catalase reduced neuronal activation in the ARC
indicated by c-Fos immunohistochemistry after hyperinsulinemic euglycemic clamp (n  4) ICV
catalase in comparison with ECF (n  3) controls; *, P  .05; **, P  .01.
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Figure 3. Arcuate POMC respond to H2O2, catalase and catalase inhibition. Before drug application in studies illustrated in A and C,
neurons were held below threshold with negative DC current of constant amplitude (5pA and [minus 8pA, respectively). A, Current clamp
recording of an arcuate POMC neuron. Bath application of H2O2 resulted in depolarization and commencement of action potential
discharge (20 mV/20 s). B, Current clamp recording of an arcuate POMC neuron. Bath application of the H2O2 scavenging enzyme catalase
resulted in hyperpolarization and cessation of action potential discharge (20 mV/2 min). C, Current clamp recording of an arcuate POMC
neuron. Bath application of the catalase inhibitor ATZ resulted in depolarization and commencement of action potential discharge (20 mV/
20 s). D, Summary of the responsiveness of arcuate POMC neurons to H2O2 (8/8), catalase (8/9), and ATZ (3/4).
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at plasma glucose levels of 3.5mM and 2.5mM (Figure
4C). Similarly, glucagon responses to hypoglycemia were
amplified and peaked at a higher plasma glucose level in
the group receiving ICV catalase, consistent with a shifted
threshold for counterregulatory responses in this group
(Figure 4D). In these hypoglycemic studies, the dextrose
infusion rates required to maintain target plasma glucose
levels did not differ significantly between the 2 groups
(Figure 4B).
Discussion
Maintaining blood glucose levels within a relatively nar-
row range is prerequisite for avoiding potentially fatal
hypoglycemia and longer-term complications associated
with hyperglycemia as seen in patients with diabetes. The
brain, in particular the hypothalamus, is involved in the
control of peripheral glucose homeostasis through regu-
lating hepatic glucose output, pancreatic insulin secretion,
and counterregulatory responses tohypoglycemia (10, 22,
23). Here, we show that brain H2O2 signaling is involved
in the central control of glucose homeostasis through reg-
ulating hepatic glucose output and counterregulatory re-
sponses to hypoglycemia.
Our findings are in keeping with our hypothesis that a
reduction in brain, and in particular hypothalamic H2O2
levels would trigger increased hepatic glucose production
because of the brain perceiving glucose levels to be lower
Figure 4. ICV infusion of catalase increased counterregulatory responses to hypoglycemia. A, Plasma glucose levels were matched between the
catalase (n  8) and ECF (n  8) groups. B, Dextrose infusion rates did not differ between the groups for the first 80 minutes of the clamp but
during the final 40 minutes, catalase-infused animals required significantly more dextrose to attain the target plasma glucose. C, ICV infusion of
catalase significantly increased the epinephrine response to hypoglycemia at plasma glucose levels of 3.5mM and 2.5mM. D, The glucagon
response to hypoglycemia was amplified and peaked at a higher plasma glucose level in the group receiving ICV catalase; *, P  .05; **, P  .01.
4674 Pauliina Markkula et al Hypothalamic ROS and Glucose Homeostasis Endocrinology, December 2016, 157(12):4669–4676
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 05 December 2016. at 06:15 For personal use only. No other uses without permission. . All rights reserved.
than they actually were. This is broadly consistent with
data from Leloup et al (11), who proposed that a rise in
blood glucose is registered through a rise in hypothalamic
ROS, leading to a rise in pancreatic insulin release. If ROS
are involved in brain insulin signaling (12, 13), it is also
possible that the effects that we observed with ICV cata-
lase were mediated by a reduction in the suggested central
actions of insulin to restrain hepatic glucose output
(10). Given the apparent overlap between glucose/sub-
strate and insulin sensing, it is possible that brain ROS
may act as a “signal of plenty” mediating both glucose
and insulin signaling.
We also observed that ICV catalase delivery pro-
moted stronger and earlier counterregulatory responses
during step-wise hypoglycemic clamps. This, too, is
consistent with the hypothesis that brain glucose sens-
ing neurons use ROS as a glucose signal so that a fall in
H2O2 signifies a fall in glucose. In this work, we have
not identified whether effects were mediated by baso-
medial hypothalamic glucose-excited or glucose-inhib-
ited neurons, or indeed both. It is likely that other brain
areas outside the hypothalamus also contribute to the
integration of counterregulatory responses to hypogly-
cemia, and it is possible that our effects may also have
been mediated through these nonhypothalamic areas
(24).However, given that the catalasewas infused to the
base of the third ventricle and given the changes in brain
activation we observed, we think that it is more likely
that the effects under these study conditions arose from
reduced ROS levels in the hypothalamus.
Although we do not unambiguously identify the
chemical phenotype of the catalase inhibited neurons, it
seems likely that at least a proportion express POMC as
previous work from Diano et al have shown that H2O2
acutely activates POMC neurons in the basomedial hy-
pothalamus (14). This is supported by our ex vivo ex-
periments which also showed that POMC neurons were
excited by ROS. Moreover, we were able to show that
POMC neurons were inhibited by catalase and excited
by catalase inhibition.
A network of glucose sensors within and outside brain
probably provide integrated information to allow the
body to maintain glucose homeostasis. Within brain, a
number of different glucose sensing cells have been iden-
tified, including POMC-expressing neurons. Although a
key role forPOMCinenergybalance is clearly established,
growing evidence suggests that POMC also play a role in
glucose homeostasis, acting on hepatic glucose balance,
insulin secretion and perhaps renal glucose excretion (25–
27). Alternatively effects might bemediated by other non-
POMC neurons exerting effects on energy homeostasis
such as agouti-related peptide or indeed other metaboli-
cally active populations of cells in the basomedial hypo-
thalamus. The intracellular pathways influenced by
H2O2 signaling remain to be identified. Previous studies
of ROS have suggested this may work through protein
kinase C and the activation of ATP-sensitive potassium
channels (implicated in pancreatic and brain glucose
sensing (28, 29).
Of note, brain ROS signaling has also been implicated
in another area of centralmetabolic homeostasis, acting in
the brain control of osmoregulation and blood pressure.
Analogous to the suggested mechanisms of action for glu-
cose homeostasis, brain ROS have been suggested both to
allow local sensing of metabolic changes (osmotic poten-
tial) (30) and the mediation of the central effects of a hor-
monal signal, with hypothalamic superoxide ion facilitat-
ing the actions of angiotensin II (31).
Furthermore, brain and peripheral ROS may also me-
diate glucose-homeostasis via actions on islet function.
Normalization of brain redox status has also been shown
to reverse pathologically increased glucose-induced insu-
lin responses in obese Zucker rats (32). These findings
parallel the role of ROS in induced insulin release at the
level of the pancreatic -cell (33, 34), a process with sim-
ilarities to glucose sensing in a subset of hypothalamic
neurons (8). Recently, ROS have also been implicated in
glucose detection by the pancreatic -cell (35).
In conclusion, our data support the growing evidence
for ROS and enzymes responsible for their metabolism in
the control of glucosehomeostasis. Furtherwork isneeded
to elucidate themolecular signaling pathways involved, to
examine whether and how these processes may become
altered in diabetes and whether this may even offer future
therapeutic potential.
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